- Home
- OGI vs ALLO Comparison
OGI vs ALLO Comparison
Compare OGI & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OGI
- ALLO
- Stock Information
- Founded
- OGI 2013
- ALLO 2017
- Country
- OGI Canada
- ALLO United States
- Employees
- OGI N/A
- ALLO N/A
- Industry
- OGI Biotechnology: Pharmaceutical Preparations
- ALLO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- OGI Health Care
- ALLO Health Care
- Exchange
- OGI Nasdaq
- ALLO Nasdaq
- Market Cap
- OGI 234.5M
- ALLO 252.9M
- IPO Year
- OGI N/A
- ALLO 2018
- Fundamental
- Price
- OGI $1.77
- ALLO $1.21
- Analyst Decision
- OGI
- ALLO Buy
- Analyst Count
- OGI 0
- ALLO 12
- Target Price
- OGI N/A
- ALLO $8.80
- AVG Volume (30 Days)
- OGI 863.0K
- ALLO 3.1M
- Earning Date
- OGI 08-13-2025
- ALLO 11-13-2025
- Dividend Yield
- OGI N/A
- ALLO N/A
- EPS Growth
- OGI N/A
- ALLO N/A
- EPS
- OGI 0.05
- ALLO N/A
- Revenue
- OGI $164,107,753.00
- ALLO N/A
- Revenue This Year
- OGI $59.31
- ALLO N/A
- Revenue Next Year
- OGI $15.12
- ALLO $100.00
- P/E Ratio
- OGI $41.54
- ALLO N/A
- Revenue Growth
- OGI 50.01
- ALLO N/A
- 52 Week Low
- OGI $0.85
- ALLO $0.86
- 52 Week High
- OGI $2.08
- ALLO $3.78
- Technical
- Relative Strength Index (RSI)
- OGI 46.32
- ALLO 45.93
- Support Level
- OGI $1.67
- ALLO $1.21
- Resistance Level
- OGI $2.05
- ALLO $1.33
- Average True Range (ATR)
- OGI 0.09
- ALLO 0.10
- MACD
- OGI -0.03
- ALLO -0.02
- Stochastic Oscillator
- OGI 20.41
- ALLO 4.41
About OGI Organigram Holdings Inc.
Organigram Global Inc is a licensed cultivator of cannabis and manufacturer of cannabis-derived goods in Canada. It is is focused on producing high-quality cannabis for adult recreational consumers. It has also developed and acquired a portfolio of legal adult-use recreational cannabis brands, including Edison, Holy Mountain, Big Bag O' Buds, SHRED, SHRED'ems, Monjour, Tremblant Cannabis, Trailblazer, BOXHOT and DEBUNK. Organigram operates facilities in Moncton, New Brunswick and Lac-Superieur, Quebec, with a dedicated edibles manufacturing facility in Winnipeg, Manitoba.
About ALLO Allogene Therapeutics Inc.
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.